Selcuk Gormez1, Refik Erdim2, Gokce Akan3, Barıs Caynak4, Cihan Duran5, Demet Gunay6, Volkan Sozer7, Fatmahan Atalar8. 1. Department of Cardiology, Acibadem Mehmet Ali Aydinlar University, Faculty of Medicine, Istanbul, Turkey. 2. Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. 3. MUHAS Genetics Laboratory, MUHAS, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania. 4. Department of Cardiovascular Surgery, Istanbul Bilim University, Istanbul, Turkey. 5. Department of Radiology, Istanbul Bilim University, Istanbul, Turkey. 6. Sisli Florence Nightingale Hospital, Department of Biochemistry, Istanbul, Turkey. 7. Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey. 8. Department of Medical Genetics, Child Health Institute, Istanbul University, Istanbul, Turkey. Electronic address: fatmahan.atalar@gmail.com.
Abstract
BACKGROUND: Cytoplasmic fatty acid-binding proteins facilitate the transport of lipids to specific compartments in cells. Fatty acid-binding protein 4 (FABP4), also known as aP2 or A-FABP, plays a key role in the development of atherosclerosis, insulin resistance, obesity, and metabolic syndrome (MS). The FABP4 polymorphisms are associated with protein expression changes in vitro and metabolic and vascular alterations in vivo. The aim of this study was to investigate the association between FABP4 messenger ribonucleic acid (mRNA) expression levels in epicardial (EAT), pericardial (PAT), and subcutaneous adipose tissues (SAT), and the extent of coronary atherosclerosis in coronary artery disease (CAD) patients with MS. Furthermore, the relationship between the extent of coronary atherosclerosis and epicardial adipose tissue volume (EATV) and FABP4 gene variations was evaluated. PATIENTS AND METHODS: A total of 37 patients undergoing coronary artery bypass grafting because of CAD (MS CAD group) and 23 non-MS patients undergoing heart valve surgery (control group) were included. Coronary angiography was performed for all patients and the extent of coronary atherosclerosis was assessed using the Sullivan's scoring system. The mRNA expression levels of FABP4 gene in EAT, PAT, and SAT, and FABP4 polymorphisms were analyzed using the quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: An increased FABP4 expression was observed in EAT and PAT of MS CAD group compared to controls. In the MS CAD group, FABP4 mRNA expression levels in EAT was 2.8-fold higher compared to PAT. The expression of FABP4 in EAT was positively correlated with the extent of atherosclerosis and EATV in MS CAD group (r = 0.588, P= 0.001, r = 0.174, P = 0.001, respectively). There were no correlations between PAT and SAT versus the extent of atherosclerosis and EATV. The FABP4 EAT mRNA expression levels were found to significantly increase in mutant allele carriers of rs1054135, whereas they significantly decreased in mutant allele carriers of rs77878271 (T-87C) in MS CAD group (P < 0.05). The extent of atherosclerosis was also found to be significantly associated with rs1054135 (P < 0.05). A cut-off point of 57.5 cm3 EATV was used indicating the presence of CAD with a significant area under the curve of 0.783%, 98% sensitivity, and 100% specificity (95% CI 0.620-0.880; P < 0.05). CONCLUSIONS: Our study results suggest that FABP4 expression in EAT is strongly associated with the extent of atherosclerosis and EATV in MS CAD patients.
BACKGROUND: Cytoplasmic fatty acid-binding proteins facilitate the transport of lipids to specific compartments in cells. Fatty acid-binding protein 4 (FABP4), also known as aP2 or A-FABP, plays a key role in the development of atherosclerosis, insulin resistance, obesity, and metabolic syndrome (MS). The FABP4 polymorphisms are associated with protein expression changes in vitro and metabolic and vascular alterations in vivo. The aim of this study was to investigate the association between FABP4 messenger ribonucleic acid (mRNA) expression levels in epicardial (EAT), pericardial (PAT), and subcutaneous adipose tissues (SAT), and the extent of coronary atherosclerosis in coronary artery disease (CAD) patients with MS. Furthermore, the relationship between the extent of coronary atherosclerosis and epicardial adipose tissue volume (EATV) and FABP4 gene variations was evaluated. PATIENTS AND METHODS: A total of 37 patients undergoing coronary artery bypass grafting because of CAD (MSCAD group) and 23 non-MSpatients undergoing heart valve surgery (control group) were included. Coronary angiography was performed for all patients and the extent of coronary atherosclerosis was assessed using the Sullivan's scoring system. The mRNA expression levels of FABP4 gene in EAT, PAT, and SAT, and FABP4 polymorphisms were analyzed using the quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: An increased FABP4 expression was observed in EAT and PAT of MSCAD group compared to controls. In the MSCAD group, FABP4 mRNA expression levels in EAT was 2.8-fold higher compared to PAT. The expression of FABP4 in EAT was positively correlated with the extent of atherosclerosis and EATV in MSCAD group (r = 0.588, P= 0.001, r = 0.174, P = 0.001, respectively). There were no correlations between PAT and SAT versus the extent of atherosclerosis and EATV. The FABP4 EAT mRNA expression levels were found to significantly increase in mutant allele carriers of rs1054135, whereas they significantly decreased in mutant allele carriers of rs77878271 (T-87C) in MSCAD group (P < 0.05). The extent of atherosclerosis was also found to be significantly associated with rs1054135 (P < 0.05). A cut-off point of 57.5 cm3 EATV was used indicating the presence of CAD with a significant area under the curve of 0.783%, 98% sensitivity, and 100% specificity (95% CI 0.620-0.880; P < 0.05). CONCLUSIONS: Our study results suggest that FABP4 expression in EAT is strongly associated with the extent of atherosclerosis and EATV in MSCADpatients.
Authors: Beatrice von Jeinsen; Lisa Ritzen; Julia Vietheer; Claudia Unbehaun; Maren Weferling; Christoph Liebetrau; Christian W Hamm; Andreas Rolf; Till Keller Journal: Cardiovasc Diabetol Date: 2020-07-29 Impact factor: 9.951
Authors: Chol Shin; Seong Hwan Kim; Jin-Seok Kim; Seon Won Kim; Jong Seok Lee; Seung Ku Lee; Robert Abbott; Ki Yeol Lee; Hong Euy Lim; Ki-Chul Sung; Goo-Yeong Cho; Kwang Kon Koh; Sun H Kim Journal: Cardiovasc Diabetol Date: 2021-01-25 Impact factor: 9.951
Authors: Jose P Lopez-Lopez; Daniel D Cohen; Daniela Ney-Salazar; Daniel Martinez; Johanna Otero; Diego Gomez-Arbelaez; Paul A Camacho; Gregorio Sanchez-Vallejo; Edgar Arcos; Claudia Narvaez; Henry Garcia; Maritza Perez; Dora I Molina; Carlos Cure; Aristides Sotomayor; Álvaro Rico; Eric Hernandez-Triana; Myriam Duran; Fresia Cotes; Darryl P Leong; Sumathy Rangarajan; Salim Yusuf; Patricio Lopez-Jaramillo Journal: Cardiovasc Diabetol Date: 2021-03-22 Impact factor: 9.951